News

Quiver AI SummaryBridgeBio Pharma, Inc. announced new data highlighting the kidney-protective benefits of acoramidis, a treatment for transthyretin amyloid…

In late February 2026, a research study by Dr Nguyen Van Te (Head of Nuclear Medicine at FV Hospital) and his colleagues was officially published in the Journal of…

Early and continuous treatment with transthyretin (TTR) stabilizer acoramidis led to significant improvements in health status and slower functional decline in…

“AL Amyloidosis Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects…

AbstractAimsWhile cardiac magnetic resonance (CMR) provides prognostic value in transthyretin cardiac amyloidosis (ATTR-CA), current ATTR-CA staging relies on serum…

Brief SummaryTransthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-…

AbstractIntroductionTransthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a major cause of heart failure, due to improved awareness of red…

AbstractBackground Cardiac amyloidosis (CA) is frequently preceded by soft tissue infiltration, manifesting as orthopaedic "red flags" such as carpal tunnel…

Cardiovascular disease, the leading cause of deathTrusted Source globally, has not yet had an early-detection test — until now. On June 22, the Food and Drug…

AbstractInterpreting composite endpoints in cardiovascular drug development is a key challenge, particularly when events of different clinical relevance are…